Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25years. EMBO Mol Med 2016, 8: 595–608.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sasmita AO, Depp C, Nazarenko T, Sun T, Siems SB, Ong EC. Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice. Nat Neurosci 2024, 27: 1668–1674.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ladiwala AR, Litt J, Kane RS, Aucoin DS, Smith SO, Ranjan S, et al. Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity. J Biol Chem 2012, 287: 24765–24773.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayer TA. Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease. Mol Psychiatry 2022, 27: 1880–1885.

Article  CAS  PubMed  Google Scholar 

Wirths O, Zampar S. Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease. Expert Opin Ther Targets 2019, 23: 991–1004.

Article  CAS  PubMed  Google Scholar 

Cai W, Li L, Sang S, Pan X, Zhong C. Physiological roles of β-amyloid in regulating synaptic function: Implications for AD pathophysiology. Neurosci Bull 2023, 39: 1289–1308.

Article  CAS  PubMed  Google Scholar 

Yoon SS, Jo SA. Mechanisms of amyloid-β peptide clearance: Potential therapeutic targets for Alzheimer’s disease. Biomol Ther 2012, 20: 245–255.

Article  CAS  Google Scholar 

Yang L, Feng S, Wu C, Yang L. Microglia-mediated aβ propagation in Alzheimer’s disease. Neurosci Bull 2022, 38: 1274–1276.

Article  PubMed  PubMed Central  Google Scholar 

Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 2021, 17: 580–589.

Article  PubMed  Google Scholar 

Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A. 1996, 93: 452–455.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schenk D. Hopes remain for an Alzheimer’s vaccine. Nature 2004, 431: 398.

Article  CAS  PubMed  Google Scholar 

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014, 370: 311–321.

Article  CAS  PubMed  Google Scholar 

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014, 370: 322–333.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther 2017, 9: 95.

Article  PubMed  PubMed Central  Google Scholar 

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimers Res Ther 2018, 10: 96.

Article  PubMed  PubMed Central  Google Scholar 

Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 2021, 17: 696–701.

Article  PubMed  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023, 388: 9–21.

Article  PubMed  Google Scholar 

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023, 330: 512–527.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saroja SR, Sharma A, Hof PR, Pereira AC. Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer’s disease. Alzheimers Dement 2022, 18: 1602–1615.

Article  CAS  PubMed  Google Scholar 

Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat Med 2021, 27: 1187–1196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Selkoe DJ. Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev 2001, 81: 741–766.

Article  CAS  PubMed  Google Scholar 

Mullard A. Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat Rev Drug Discov 2021, 20: 3–5.

Article  CAS  PubMed  Google Scholar 

Murdock MH, Yang CY, Sun N, Pao PC, Blanco-Duque C, Kahn MC, et al. Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature 2024, 627: 149–156.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Munoz-Mayorga D, Nie Y, Kang N, Tao Y, Lagerwall J, et al. Microglial lipid droplet accumulation in tauopathy brain is regulated by neuronal AMPK. Cell Metab 2024, 36: 1351-1370.e8.

Article  CAS  PubMed  Google Scholar 

Bu XL, Jiao SS, Lian Y, Wang YJ. Perspectives on the tertiary prevention strategy for Alzheimer’s disease. Curr Alzheimer Res 2016, 13: 307–316.

Article  CAS  PubMed  Google Scholar 

Liu J, van Beusekom H, Bu XL, Chen G, Henrique Rosado de Castro P, Chen X, et al. Preserving cognitive function in patients with Alzheimer’s disease: The Alzheimer’s disease neuroprotection research initiative (ADNRI). Neuroprotection 2023, 1: 84–98.

Article  PubMed  PubMed Central  Google Scholar